Age-adjusted Charlson comorbidity index score is the best predictor for severe clinical outcome in the hospitalized patients with COVID-19 infection: a result from nationwide database of 5,621 Korean patients

Do Hyoungh Kim^{†1,2}, Hayne Cho Park^{†1,2}, Ajin Cho^{1,2}, Juhee Kim¹, Kyu-sang Yun¹, Jinseog Kim³, Young-Ki Lee^{1,2}

¹Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.

²Hallym University Kidney Research Institute, Seoul, Korea.

³Department of Bigdata and Applied Statistics, Dongguk University, Gyeongju, Korea.

[†]Do Hyoungh Kim and Hayne Cho Park contributed equally to this work.

CORRESPONDENCE:

Young-Ki Lee

Address: 1, Singil-ro, Yeongdeungpo-gu, Seoul, 07441, Korea

Phone: (Int. +82-2) 829-5214

E-mail: km2071@naver.com

20 ABSTRACT

21 Aged population with comorbidities demonstrated high mortality rate and severe clinical
 22 outcome in the patients with coronavirus disease 2019 (COVID-19). However, whether age-
 23 adjusted Charlson comorbidity index score (CCIS) predict fatal outcomes remains uncertain.
 24 This retrospective, nationwide cohort study was performed to evaluate patient mortality and
 25 clinical outcome according to CCIS among the hospitalized patients with COVID-19
 26 infection. We included 5,621 patients who had been discharged from isolation or had died
 27 from COVID-19 by April 30, 2020. The primary outcome was composites of death,
 28 admission to intensive care unit (ICU), use of mechanical ventilator or extracorporeal
 29 membrane oxygenation. The secondary outcome was mortality. Multivariate Cox
 30 proportional hazard model was used to evaluate CCIS as the independent risk factor for death.
 31 Among 5,621 patients, the high CCIS (≥ 3) group showed higher proportion of elderly
 32 population and lower plasma hemoglobin and lower lymphocyte and platelet counts. The
 33 high CCIS group was an independent risk factor for composite outcome (HR 3.63, 95% CI
 34 2.45-5.37, $P < 0.001$) and patient mortality (HR 22.96, 95% CI 7.20-73.24, $P < 0.001$). The
 35 nomogram demonstrated that the CCIS was the most potent predictive factor for patient
 36 mortality. The predictive nomogram using CCIS for the hospitalized patients with COVID-19
 37 may help clinicians to triage the high-risk population and to concentrate limited resources to
 38 manage them.

39 INTRODUCTION

40 The coronavirus disease 2019 (COVID-19) has been declared as a pandemic by the
41 World Health Organization in March 2020¹, and as of July 31, 2020, 16,864,828 people have
42 been affected by the virus and 663,580 deaths were reported worldwide². The Korean Centers
43 for Disease Control and Prevention (KCDC) and relevant organization prepared policies for
44 management for the COVID-19 outbreak as soon as the first case of COVID-19 was reported
45 in Korea³. The Korean government not only performed extensive confirmatory tests for those
46 who are suspected to have the disease but also implemented strict social distancing to prevent
47 further transmission of disease. As the results, mild cases among young and healthy
48 population were diagnosed as COVID-19 by screening tests but subsequent case fatality rate
49 revealed lower than those reported worldwide. As of July 31, there were 14,269 confirmed
50 cases of COVID-19 and 300 deaths in Korea (case fatality rate of 2.1% in Korea vs. 3.9% in
51 average worldwide)⁴.

52 Nevertheless, there were some population with higher morbidity and mortality during
53 COVID-19 outbreak. The situation reports from KCDC demonstrated that higher mortality
54 among the patients with advanced age⁴. It is reasonable to think that the patients with
55 advanced age show higher mortality because of reduced immunity and higher comorbidities
56 such as diabetes or chronic kidney disease. Previous reports suggested old age and multiple
57 comorbidities are independently associated with higher mortality⁵⁻⁷. However, most of the
58 studies demonstrated individual category of disease such as diabetes or coronary heart disease
59 as a risk factor but not weighted the effect of age and severity of multimorbidity as predictors
60 of poor clinical outcomes.

61 Age-adjusted Charlson comorbidity index score (CCIS) has been developed and

validated to predict the risk of mortality for use in longitudinal studies⁸. The score can be calculated from a weighted index consisted of age and the number and seriousness of comorbid diseases. The CCIS has been widely used to predict 10-year mortality among hospitalized patients⁸. The CCIS also has been validated in a various disease conditions such as acute stroke^{9,10}, leukemia¹¹, end stage renal disease^{12,13}, and hip fracture^{14,15}.

Recently, KCDC released COVID-19 database to the public. The database contains the clinical and epidemiologic data of 5,628 confirmed cases as well as their clinical outcome until April 30, 2020. We evaluated patient mortality and clinical outcome according to CCIS among the hospitalized patients with COVID-19 in Korea.

RESULTS

Baseline characteristics of the Korean COVID-19 cohort

The baseline characteristics of 5,621 patients are shown in Table 1. The mean duration from diagnosis to death or release from isolation was 25.6 days. The patients in 50s was the largest age group followed by those in 20s (Figure 1). The 3,304 (58.8%) patients were female. Female was predominant throughout all age groups except those younger than 20. Hypertension (21.3%) and diabetes mellitus (12.3%) were the most common two comorbidities. It was followed by dementia (4.2%), chronic heart disease (3.2%), malignancy (2.5%), asthma (2.3%), chronic liver disease (1.5%), congestive heart failure (1.0%), chronic kidney disease (1.0%), chronic obstructive pulmonary disease (0.7%), and connective tissue disease (0.7%) (Figure 1). The patients with low systolic blood pressure (BP) (<120mmHg) and diastolic BP (<80mmHg) were 1317 (24.0%) and 2113 (38.5%), respectively. Among 5621 confirmed cases, asymptomatic infection comprised of 25.8%. Among symptomatic

85 patients, three most common symptoms were cough (41.7%), sputum (28.8%), and febrile
86 sense (23.2%).

87 The median score of CCIS was 2 (IQR, 0-3). The number of patients in CCIS score 0, 1-2, 3-
88 4, ≥ 5 group was 1,890 (33.6%), 1,791 (31.9%), 1,399 (24.9%), and 541 (9.6%), respectively.
89 Compared to the low CCIS group (<3), the high CCIS group (≥ 3) showed higher proportion
90 of elderly patients and medical comorbidities. Presence of dyspnea, altered mentality, and
91 nausea/vomiting at admission were more frequent in the high CCIS group. In addition, the
92 number of lymphocyte and platelet count and plasma hemoglobin (Hb) level were
93 significantly lower in high CCIS group compared to low CCIS group.

94

95 **Clinical outcomes according to CCIS**

96 Composite events occurred in 368 patients (6.6 %) during the follow up period including 234
97 (4.2 %) deaths, 187 (3.3 %) admission cases of intensive care unit (ICU), 52 (0.9 %) cases of
98 mechanical ventilation, and 11 (0.2%) cases of extracorporeal membrane oxygenation
99 (ECMO) application. The composite outcomes occurred more frequently in high CCIS
100 groups showing 178 patients (32.9 %) in CCIS ≥ 5 followed by 135 (9.7%) in CCIS 3-4, 36
101 (2.0%) in CCIS 1-2, and 19 (1.0%) in CCIS 0 (Table 2). The mortality rate was also higher in
102 high CCIS groups demonstrating 154 patients (28.5%) in CCIS ≥ 5 followed by 68 (4.9%) in
103 CCIS 3-4, 11 (0.6%) in CCIS 1-2, and 1 (0.1%) in CCIS 0 (Figure 2).

104

105 **Risk factors for severe clinical outcomes**

106 We performed multivariate Cox proportional analysis to find out high CCIS ≥ 3 was an

independent risk factor for composite outcome (hazard ratio (HR), 3.63 [95% confidence interval (CI), 2.45-5.37], $P < 0.001$) together with male sex (HR, 1.76 [95% CI 1.32–2.34], $P < 0.001$), body mass index (BMI) $< 18.5 \text{ kg/m}^2$ (HR, 2.36 [95% CI 1.49–3.75], $P < 0.001$), presence of dyspnea (HR, 2.88 [95% CI 2.16–3.83], $P < 0.001$), lymphopenia (HR, 2.15 [95% CI 1.59-2.91], $P < 0.001$), and anemia (HR, 1.80 [95% CI 1.33-2.43], $P < 0.001$) (See Figure 3 and Supplementary Table S1 online).

Then, we analyzed the risk factors for mortality (see Supplementary Figure S1 online). The patients older than 70 years old demonstrated higher mortality risk compared younger patients. The patients with high CCIS ≥ 3 also showed higher risk for mortality compared to low CCIS group. When we assessed the risk factors for mortality in univariate analysis, old age ≥ 70 years, male sex, high CCIS ≥ 3 , anemia, lymphopenia, and thrombocytopenia were significantly associated with higher mortality rate. In multivariate Cox proportional analysis, risk of mortality was higher in patients with CCIS ≥ 3 (HR, 22.96 [95% CI 7.20 - 73.24], $P < 0.001$), male sex (HR, 1.55 [95% CI 1.05–2.29], $P = 0.027$), BMI $< 18.5 \text{ kg/m}^2$ (HR, 2.88 [95% CI 1.66–4.99], $P < 0.001$), presence of dyspnea (HR, 2.90 [95% CI 1.96–4.29], $P < 0.001$), lymphopenia (HR, 2.61 [95% CI 1.75-3.89], $P < 0.001$), anemia (HR, 2.08 [95% CI 1.40-3.11], $P < 0.003$), and thrombocytopenia (HR, 2.03 [95% CI 1.35–3.04], $P < 0.001$) (Figure 3).

Prediction model for case fatality

The predictive nomogram was constructed based on the multivariate Cox analysis for mortality. To calculate 14-, and 28-day overall survival probability was calculated from the summed points of sex, BMI, CCIS, presence of dyspnea, plasma Hb, lymphopenia, and thrombocytopenia (Figure 4). The nomogram showed that CCIS was the most important

factor contributing to the prognosis followed by the presence of dyspnea, low BMI <18.5 kg/m², lymphopenia (<0.8 x10⁹/L), thrombocytopenia (<150.0 x10⁹/L), anemia (<12.0 g/dL), and male sex. The Harrell concordance index (C-index) value for prediction of overall survival was 0.933, and R² value was 0.991 in 14-day and 0.990 in 28-day prediction model (see Supplementary Figure S2 online).

DISCUSSION

In this study, we described the effect of age and comorbidity upon composites of severe clinical outcomes (death, ICU admission, mechanical ventilation, or ECMO) among the hospitalized patients with COVID-19. The patients with high CCIS showed older age, lower plasma level of Hb, and lower lymphocyte and platelet counts. The high CCIS (≥3) group was an independent risk factors for composite outcome (HR 3.63, 95% CI 2.45-5.37, p<0.0001) and patient mortality (HR 7.05, 95% CI 2.13-23.33, p=0.0014).

Korean COVID-19 cohort demonstrated large proportion of younger population with age <50 (34.7%) and asymptomatic confirmed cases (25.7%). The patients without any comorbidities (CCIS 0) comprised of 33.1% of total population. Median CCIS was 2 for the Korean COVID-19 cohort. Previous report from Wuhan, China demonstrated higher proportion of younger population with age <50 (56.0%) as well as greater proportion of the patients without any comorbidities (76.3%)¹⁶. The brief report from Danish population also demonstrated that higher proportion of confirmed cases without any comorbidities (CCIS 0, 65.0%)¹⁷. On the other hands, previous papers from United States of America demonstrated higher proportion of older people (mean age of 61.0) and lower proportion of the patients without existing comorbidities (27.4%)¹⁸. In Italy where one of the highest case fatality rates

were reported, the non-survivor demonstrated advanced age (79.6 ± 0.9 years vs. 64.7 ± 0.4 years, $p=0.0001$) and higher CCIS (4.3 ± 0.15 vs. 2.6 ± 0.05 , $p=0.0001$) compared to survivors⁵.

The observed differences of baseline characteristics among various countries may be related not only to patient demographics but also the degree of performing active screening tests against asymptomatic population.

Our study is the first large nationwide cohort study to demonstrate that CCIS is the best predictor for severe clinical outcome in the patients with COVID-19. Previous paper by Chen et al. demonstrated that advanced age is the strongest risk factor for a fatal outcome⁶. In addition to advanced age, preexisting comorbid conditions including coronary heart disease and cerebrovascular disease, shortness of breath, and levels of procalcitonin and aspartate aminotransferase were related to fatal outcome. However, previous study by Zhou et al. presented only advanced age but not comorbidity was an independent risk factor for mortality¹⁹. Another study by Ji et al. also evaluated the risk factors for progression risk of pneumonia in COVID-19 patients²⁰. They showed that presence of comorbidities and advanced age both contribute to higher risk of disease progression. Korean group also recently published the paper about the impact of comorbidities upon the mortality^{7,21}. However, these studies did not use CCIS to calculate the weight of the comorbidities. There were several studies suggesting CCIS as an independent risk factor for hospitalization or patient mortality among the patients with COVID-19^{17,18,22}. However, to our knowledge, there was no study showing prediction model of fatal outcome using CCIS.

In the same vein with previous studies, the advanced age >50 years old demonstrated high risk of mortality and ICU admission. The previous study performed by Sung et al. showed relatively young patients under age 50 recovered without oxygen therapy or ICU care²³. On the other hands, the patients of ≥ 50 years of age demonstrated high case fatality rate reaching

14% in the patients over 80 years old. Our study also confirmed that advanced age itself is an independent factor for composites of severe clinical outcome.

There are some limitations to our study. First, the nationwide database from KCDC only offered limited data. For example, there are no information about chest radiograph findings or laboratory findings such as C-reactive protein or serum creatinine. Therefore, we could not adjust potential risk factors in our study. Second, due to the nature of survey without collecting actual previous medical history from ICD-10 diagnosis code, some information about comorbidities are missing. Therefore, we modified some categories of chronic illness included in the original CCIS. For example, we scored all forms of coronary artery disease including myocardial infarction and chronic heart disease with a score of 1. Previous report also demonstrated the usefulness of modified form of CCIS in prediction of clinical outcome in renal patients²⁴. In addition, the information about some chronic conditions such as peripheral vascular disease, cerebrovascular disease or peptic ulcer disease were missing. We calculated CCIS based on the available data excluding those categories of missing data. Therefore, CCIS in our cohort may be underestimated than actual CCIS. Lastly, there can be ethnic or racial difference in clinical outcomes of COVID-19. Therefore, our result may not be applicated to the different ethnicity or population. However, recent paper suggested that racial difference did not contribute to different clinical outcome²². Nevertheless, there should be a validation test in each population using our predictive tool before clinical application.

In conclusion, our study provided convenient predictive tool using CCIS for the hospitalized patients with COVID-19 to calculate the risk of severe clinical outcome at admission. The CCIS together with initial symptom and laboratory findings may lead us to triage the patients most likely to progress and concentrate our efforts to save their lives.

200

201 **METHODS**

202 **Study design and participants**

203 This is a retrospective cohort study using the nationwide COVID-19 database provided by
 204 KCDC. A total of 5,628 patients were included in the database who had been confirmed to
 205 have COVID-19 and had received treatment from 100 hospitals until April 30, 2020. Among
 206 them, 7 patients who were confirmed for COVID-19 after death were excluded, and a total of
 207 5,621 patients were included in the analysis. According to the definition provided by the
 208 KCDC²⁵, the confirmed case was defined as a patient who had been confirmed to be infected
 209 with COVID-19 by real-time reverse transcriptase-polymerase chain reaction assay or virus
 210 isolation from nasal and/or pharyngeal swab specimens regardless of the clinical symptoms.
 211 The study protocol was reviewed and approved by the Institutional Review Board of the
 212 Kangnam Sacred Heart Hospital, Seoul, Korea (HKS 2020-06-025). The informed consent
 213 was waived due to retrospective nature of the study.

214

215 **Data collection**

216 Clinical and epidemiological data were collected in a retrospective manner and were
 217 anonymized before release. Demographic data including age by decade, sex, survival status,
 218 and duration of isolation were collected. Information about whether the patient was admitted
 219 to ICU or applied mechanical ventilator or ECMO were also collected. The BMI, systolic and
 220 diastolic BP, heart rate, and body temperature at initial visit were also measured and reported.
 221 The clinical symptoms associated with COVID-19 were reported including febrile sense,

cough, sputum, sore throat, rhinorrhea, myalgia, shortness of breath, headache, altered consciousness/confusion, nausea or vomiting, diarrhea. Laboratory assessments consisted of plasma Hb, white blood cell, lymphocyte, and platelet count. The categories of comorbidities were assessed including diabetes mellitus, hypertension, heart failure, chronic heart disease, asthma, chronic obstructive pulmonary disease, chronic kidney disease, malignancy, chronic liver disease, connective tissue disease, and dementia. The CCIS was calculated using the method described in the previous study^{8,24}. Due to lack of available data, all kinds of chronic heart disease were considered to have congestive heart failure and all forms of chronic liver disease were considered to have mild liver disease. The presence of peripheral vascular disease, cerebrovascular disease, peptic ulcer disease, hemiplegia, end-stage renal disease, or acquired immunodeficiency syndrome could not be known from the current database. All kinds of malignancy were considered non-metastatic.

Study outcomes

The primary endpoint was defined as the composite of death, admission to ICU, application of mechanical ventilation or ECMO. The secondary endpoints were patient mortality and ICU admission rate. The primary and secondary endpoints were compared between low and high CCIS groups. Finally, we established a prediction model for patient mortality through risk factor analysis.

Statistical Analysis

The baseline characteristics and clinical outcomes were compared among CCIS groups. We

divided the patients into 4 groups according to CCIS: CCIS 0, 1-2, 3-4, and ≥ 5 . The normally distributed numerical variables were expressed as the mean $\pm$ standard deviation, whereas variables with skewed distributions were expressed as the median and interquartile range. Statistical comparisons between continuous variables were performed with an independent Student t-test or one-way analysis of variance for more than two group. For the data without normal distribution, the Wilcoxon Signed Rank Test for two groups or Kruskal Wallis Test for more than two groups were performed. The χ^2 test and Fisher exact test were applied to categorical variables as appropriate.

The Kaplan-Meier method was used to compare composite events-free survival curves, and differences were assessed utilizing the log-rank test. We used univariate and multivariate Cox proportional hazard model to estimate risk factors associated with composite outcome and patient mortality. Age was excluded from the multivariate analysis because of its potential interaction with CCIS. We used univariate and multivariate logistic regression models to evaluate the risk factors for ICU admission or use of mechanical ventilation. We used categorical variables to assess independent risk factors for clinical outcomes as follows: age group of <50 (reference), 50-69, and ≥ 70 years, female (reference) vs. male, BMI ≥ 18.5 (reference) vs. <18.5 kg/m², systolic BP ≥ 120 (reference) vs. <120 mmHg, diastolic BP ≥ 80 (reference) vs. <80 mmHg, heart rate <100 (reference) vs. ≥ 100 beats per minute, body temperature <37.5 (reference) vs. $\geq 37.5^\circ\text{C}$, CCIS <3 (Reference) vs. ≥ 3 points, lymphocyte count ≥ 0.8 (reference) vs. <0.8 $\times 10^9/\text{L}$, Hb ≥ 12.0 (reference) vs. <12.0 g/dL, and platelet count ≥ 150.0 (reference) vs. <150.0 $\times 10^9/\text{L}$.

A nomogram to predict 14-day and 28-day mortality risk of the patient was built based on the variables found in multivariate Cox proportional hazard model. In the nomogram, CCIS was used as a variable as a continuous variable to check the impact per CCIS. The maximum

268 score of each variable was set as 100. The performance of the nomogram was measured
 269 based on the C-index. The nomogram was validated in calibration plots with 1,000 bootstrap
 270 samples in which the estimated survival probability was compared with the observed value.
 271 All statistical analysis was performed by using R version 4.0.2 (R Foundation for Statistical
 272 Computing; <http://www.r-project.org/>). P value < 0.05 was considered statistically significant.

273

274 **Data Availability Statement**

275 The data that support the findings of this study are available from KCDC, but restrictions
 276 apply to the availability of these data and so are not publicly available. Data are however
 277 available from the authors upon request and with permission of KCDC.

REFERENCES

- 1 WHO. *Novel Coronavirus (2019-nCoV) Situation Report-51*,
<https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10> (2020).
- 2 WHO. *Novel Coronavirus (2019-nCoV) Situation Report-186*,
<https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200724-covid-19-sitrep-186.pdf?sfvrsn=4da7b586_2> (2020).
- 3 Park, H. C. *et al.* Korean clinical practice guidelines for preventing transmission of coronavirus disease 2019 (COVID-19) in hemodialysis facilities. *Kidney Res Clin Pract* **39**, 145-150, doi:10.23876/j.krcp.20.046 (2020).
- 4 KCDC. *Updates on COVID-19 in Republic of Korea(as of 29 July)*,
<http://ncov.mohw.go.kr/en/tcmBoardList.do?brdId=12&brdGubun=125&dataGubun=&ncvContSeq=&contSeq=&board_id=> (2020).
- 5 Iaccarino, G. *et al.* Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension. *Hypertension* **76**, 366-372, doi:10.1161/HYPERTENSIONAHA.120.15324 (2020).
- 6 Chen, R. *et al.* Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. *Chest* **158**, 97-105, doi:10.1016/j.chest.2020.04.010 (2020).
- 7 Kim, D. W., Byeon, K. H., Kim, J., Cho, K. D. & Lee, N. The Correlation of Comorbidities on the Mortality in Patients with COVID-19: an Observational Study Based on the Korean National Health Insurance Big Data. *J Korean Med Sci* **35**, e243, doi:10.3346/jkms.2020.35.e243 (2020).
- 8 Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of

302 classifying prognostic comorbidity in longitudinal studies: development and
303 validation. *J Chronic Dis* **40**, 373-383, doi:10.1016/0021-9681(87)90171-8 (1987).

304 9 Liu, H. *et al.* Effect of Comorbidity Assessed by the Charlson Comorbidity Index on
305 the Length of Stay and Mortality Among Immobile Hemorrhagic Stroke Patients
306 Younger Than 50 Years. *Front Neurol* **11**, 487, doi:10.3389/fneur.2020.00487 (2020).

307 10 Ofori-Asenso, R. *et al.* Effect of Comorbidity Assessed by the Charlson Comorbidity
308 Index on the Length of Stay, Costs and Mortality among Older Adults Hospitalised for
309 Acute Stroke. *Int J Environ Res Public Health* **15**, doi:10.3390/ijerph15112532 (2018).

310 11 Dhakal, P. *et al.* Usefulness of Charlson Comorbidity Index to Predict Early Mortality
311 and Overall Survival in Older Patients With Acute Myeloid Leukemia. *Clin*
312 *Lymphoma Myeloma Leuk*, doi:10.1016/j.clml.2020.07.002 (2020).

313 12 Park, J. Y. *et al.* Comorbidities Can Predict Mortality of Kidney Transplant Recipients:
314 Comparison With the Charlson Comorbidity Index. *Transplant Proc* **50**, 1068-1073,
315 doi:10.1016/j.transproceed.2018.01.044 (2018).

316 13 Chae, J. W. *et al.* Prediction of mortality in patients undergoing maintenance
317 hemodialysis by Charlson Comorbidity Index using ICD-10 database. *Nephron Clin*
318 *Pract* **117**, c379-384, doi:10.1159/000321525 (2011).

319 14 Toson, B., Harvey, L. A. & Close, J. C. The ICD-10 Charlson Comorbidity Index
320 predicted mortality but not resource utilization following hip fracture. *J Clin*
321 *Epidemiol* **68**, 44-51, doi:10.1016/j.jclinepi.2014.09.017 (2015).

322 15 Kirkland, L. L., Kashiwagi, D. T., Burton, M. C., Cha, S. & Varkey, P. The Charlson
323 Comorbidity Index Score as a predictor of 30-day mortality after hip fracture surgery.
324 *Am J Med Qual* **26**, 461-467, doi:10.1177/1062860611402188 (2011).

325 16 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N*

326 *Engl J Med* **382**, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).

327 17 Christensen, D. M. *et al.* Charlson Comorbidity Index Score and Risk of Severe
328 Outcome and Death in Danish COVID-19 Patients. *J Gen Intern Med*,
329 doi:10.1007/s11606-020-05991-z (2020).

330 18 Imam, Z. *et al.* Older age and comorbidity are independent mortality predictors in a
331 large cohort of 1305 COVID-19 patients in Michigan, United States. *J Intern Med*,
332 doi:10.1111/joim.13119 (2020).

333 19 Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with
334 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054-1062,
335 doi:10.1016/S0140-6736(20)30566-3 (2020).

336 20 Ji, D. *et al.* Prediction for Progression Risk in Patients with COVID-19 Pneumonia:
337 the CALL Score. *Clin Infect Dis*, doi:10.1093/cid/ciaa414 (2020).

338 21 Cho, J. H. *et al.* Hemodialysis with Cohort Isolation to Prevent Secondary
339 Transmission during a COVID-19 Outbreak in Korea. *J Am Soc Nephrol* **31**, 1398-
340 1408, doi:10.1681/ASN.2020040461 (2020).

341 22 Price-Haywood, E. G., Burton, J., Fort, D. & Seoane, L. Hospitalization and Mortality
342 among Black Patients and White Patients with Covid-19. *N Engl J Med* **382**, 2534-
343 2543, doi:10.1056/NEJMsa2011686 (2020).

344 23 Sung, H. K. *et al.* Clinical Course and Outcomes of 3,060 Patients with Coronavirus
345 Disease 2019 in Korea, January-May 2020. *J Korean Med Sci* **35**, e280,
346 doi:10.3346/jkms.2020.35.e280 (2020).

347 24 Beddhu, S., Bruns, F. J., Saul, M., Seddon, P. & Zeidel, M. L. A simple comorbidity
348 scale predicts clinical outcomes and costs in dialysis patients. *Am J Med* **108**, 609-613,
349 doi:10.1016/s0002-9343(00)00371-5 (2000).

350 25 KCDC. *Patient treatment and management: case definitions,*
351 http://ncov.mohw.go.kr/en/baroView.do?brdId=11&brdGubun=112&dataGubun=&ncvContSeq=&contSeq=&board_id=
352 http://ncov.mohw.go.kr/en/baroView.do?brdId=11&brdGubun=112&dataGubun=&ncvContSeq=&contSeq=&board_id= (2020).

353   **Acknowledgements**

354   We acknowledge all the health-care workers involved in the diagnosis and treatment of
355   COVID-19 patients in South Korea. We thank the Central Disease Control Headquarters,
356   National Medical Center and the Health Information Manager in 100 hospitals for their effort
357   in collecting the medical records. There was no specific funding for this work.

358

359   **Authors'contributions**

360   All authors participated in the research and preparation of the manuscript. K.D.H. and P.H.C.
361   equally contributed to this manuscript as 1st authors who drafted this paper. P.H.C. and L.Y.K.
362   contributed to the conception of the work and study design. K.J.S. contributed to statistical
363   analyses and producing tables and figures. K.D.H., K.J., and Y.K.S. contributed to the
364   acquisition of data and manipulating the data to the analyzable format. L.Y.K. had full access
365   to all the data in the study and take responsibility for the integrity and accuracy of the data.
366   C.A. and L.Y.K. supervised the work and revised the manuscript.

367

368   **Competing interests**

369   The authors declare that they have no competing interests.

FIGURE LEGENDS

Figure 1. Demographic distribution of the patients with COVID-19 in Korea. A. Age and sex distribution; B. Proportion of underlying comorbidities.

The patients in 50s was the largest age group followed by those in 20s. Female was predominant throughout all age groups except those younger than 20. Hypertension (21.3%) and diabetes mellitus (12.3%) were the most common two comorbidities. It was followed by dementia (4.2%), chronic heart disease (3.2%), malignancy (2.5%), asthma (2.3%), chronic liver disease (1.5%), congestive heart failure (1.0%), chronic kidney disease (1.0%), chronic obstructive pulmonary disease (0.7%), and connective tissue disease (0.7%)

Abbreviations. CHF, Congestive heart failure; CKD, Chronic kidney disease; CLD, Chronic liver disease; COPD, Chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CTD, Connective tissue disease; HTN, hypertension.

Figure 2. Proportion of death according to CCIS of patients with COVID-19.

The morality rate increased as CCIS increases. The mortality rate was 28.5% in CCIS ≥ 5 followed by 4.9% in CCIS 3-4, 0.6% in CCIS 1-2, and 0.1% in CCIS 0.

Abbreviations. CCIS, age-adjusted Charlson comorbidity index score; COVID-19, coronavirus disease 2019.

Figure 3. Risk factor for severe clinical outcomes in the patients with COVID-19. A. Risk factors for the composite outcome; B. Risk factors for patient mortality.

391 Multivariate Cox proportional hazard model demonstrated CCIS is an independent risk factor
392 for composite outcome and mortality after adjusting other risk factors.

393 *Abbreviations.* BMI, body mass index; BP blood pressure; CCIS, age-adjusted Charlson
394 comorbidity index score; CI, confidence interval; COVID-19, coronavirus disease 2019.

395

396 **Figure 4. Prognostic nomogram for prediction of the overall survival probability of**
397 **patients with COVID-19.**

398 The nomogram demonstrates CCIS is the potent predictor for 14-day and 24-day survival of
399 the patients.

400 *Abbreviations.* BMI, body mass index; CCIS, age-adjusted Charlson comorbidity index score;
401 COVID-19, coronavirus disease 2019.

A **B**

A **B**